Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities
Explaining the need for these changes,
The company announced the following changes:
Christi Shaw has been hired to lead the company's Bio-Medicines business beginningApril 3 . Shaw will succeed Ricks, who became Lilly's president and CEO onJanuary 1 , as senior vice president and president of Lilly Bio-Medicines. Shaw, who started her career at Lilly in 1989, has more than 25 years of pharmaceutical and medical device experience.- Beginning on
February 1 , Lilly's Diabetes, Oncology and Bio-Medicines human pharmaceutical therapeutic business areas will assume commercial responsibility for their products in China—in addition to theU.S. , Japanese and Canadian markets in which they already operate. - Lilly Diabetes will host the company's human pharmaceutical commercial operations in
the United States ,China ,Japan andCanada .Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes, will assume additional responsibilities as president ofLilly USA . - Lilly's current Emerging Markets business will combine with
Europe to formLilly International , which will have commercial responsibility for the company's human pharmaceutical products in these markets.Alfonso (Chito) Zulueta , who has led the Emerging Markets business for the last three years, will be senior vice president of Lilly and president ofLilly International . Sue Mahony , Ph.D., will continue as senior vice president of Lilly and president of Lilly Oncology.Alex Azar , president ofLilly USA , has decided to leave Lilly to pursue other career opportunities.
These organizational changes are expected to increase productivity and simplify Lilly's global commercial organization. These changes will also result in a reduction in leadership positions. In December, the company announced reductions to its
"With new medicines recently launched—and potential new medicines in development for cancer, diabetes, autoimmune diseases, neurodegeneration, and pain—Lilly is in the early stages of a new growth period," said Ricks. "Now is the time to make sure that our organization is set up to make the most of these opportunities. With clear priorities and the right structure, achieving growth while improving our productivity will go hand-in-hand."
"I'm confident that these changes will help to increase the flow of innovation from our pipeline and maximize opportunities in priority therapeutic and geographic areas," Ricks said.
About Shaw and Azar
In her new role, Shaw will lead important areas of potential growth for Lilly—immunology, neurodegeneration, and pain, as well as many of the company's established brand products.
"I'm excited to welcome
Shaw worked at Lilly from 1989 to 2002 in sales and marketing roles. Most recently, she served as president of
"It's wonderful to be home again at Lilly," Shaw said. "There's no place in our industry I'd rather be today. With its extraordinary portfolio and promising late-stage pipeline, Lilly is in a strong position to make life better for patients dealing with some of the most challenging diseases."
Ricks also commented, "I want to take this opportunity to thank
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. C-LLY
This press release contains forward-looking statements about the benefits of leadership changes and organizational structure adjustments within Lilly's human pharmaceutical business. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of these adjustments or leadership changes. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the
Refer to: |
|
|
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-to-adjust-organization-and-leadership-structure-to-better-align-with-growth-opportunities-300386251.html
SOURCE
News Provided by Acquire Media